Aurinia

Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, Aurinia introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company's corporate headquarters is located in Edmonton, Alberta, Canada, with a United States office in Rockville, Maryland.

Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, Aurinia introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

1. 1Our Company | Aurinia Pharmaceuticals Inc. (AUPH)auriniapharma.com
2. 2Contact Us | Aurinia Pharmaceuticals Inc. (AUPH)auriniapharma.com
3. 3Aurinia (NASDAQ: AUPH) raises revenue outlook but third-quarter profit stays flatdailypolitical.com
4. 4Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlightsfinancialpost.com
5. 5Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlightsinvestingnews.com
6. 6Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlightsfinancialpost.com
7. 7Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlightsbiospace.com